CL2018000745A1 - Sales y formas solidas del acido 1-(((z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoazetidin-3-il)amino)etilideno)amino)oxi)ciclopropanocarboxilico; metodos de preparacion; formas cristalinas; composicion farmaceutica; uso en el tratamiento de una infeccion bacteriana gram negativa. - Google Patents
Sales y formas solidas del acido 1-(((z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoazetidin-3-il)amino)etilideno)amino)oxi)ciclopropanocarboxilico; metodos de preparacion; formas cristalinas; composicion farmaceutica; uso en el tratamiento de una infeccion bacteriana gram negativa.Info
- Publication number
- CL2018000745A1 CL2018000745A1 CL2018000745A CL2018000745A CL2018000745A1 CL 2018000745 A1 CL2018000745 A1 CL 2018000745A1 CL 2018000745 A CL2018000745 A CL 2018000745A CL 2018000745 A CL2018000745 A CL 2018000745A CL 2018000745 A1 CL2018000745 A1 CL 2018000745A1
- Authority
- CL
- Chile
- Prior art keywords
- oxo
- amino
- sulfoazetidin
- oxooxazolidin
- aminothiazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562222430P | 2015-09-23 | 2015-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018000745A1 true CL2018000745A1 (es) | 2018-06-22 |
Family
ID=58385723
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018000745A CL2018000745A1 (es) | 2015-09-23 | 2018-03-21 | Sales y formas solidas del acido 1-(((z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoazetidin-3-il)amino)etilideno)amino)oxi)ciclopropanocarboxilico; metodos de preparacion; formas cristalinas; composicion farmaceutica; uso en el tratamiento de una infeccion bacteriana gram negativa. |
CL2019003324A CL2019003324A1 (es) | 2015-09-23 | 2019-11-20 | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019003324A CL2019003324A1 (es) | 2015-09-23 | 2019-11-20 | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) |
Country Status (25)
Country | Link |
---|---|
US (1) | US10919887B2 (es) |
EP (1) | EP3353175B1 (es) |
JP (1) | JP6837480B2 (es) |
KR (1) | KR20180054816A (es) |
CN (1) | CN108137573B (es) |
AU (1) | AU2016327264B2 (es) |
CA (1) | CA2999794C (es) |
CL (2) | CL2018000745A1 (es) |
CY (1) | CY1123509T1 (es) |
DK (1) | DK3353175T3 (es) |
EA (2) | EA037569B1 (es) |
ES (1) | ES2817537T3 (es) |
HK (1) | HK1257271A1 (es) |
HR (1) | HRP20201423T1 (es) |
HU (1) | HUE050849T2 (es) |
IL (1) | IL258254B (es) |
LT (1) | LT3353175T (es) |
MA (1) | MA42946B1 (es) |
MX (1) | MX2018003592A (es) |
PH (1) | PH12018500653A1 (es) |
PT (1) | PT3353175T (es) |
RS (1) | RS60805B1 (es) |
RU (1) | RU2754180C2 (es) |
SI (1) | SI3353175T1 (es) |
WO (1) | WO2017050218A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3661933B1 (en) * | 2017-08-02 | 2022-03-23 | Novartis AG | Process for preparing 1-(((z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid |
US11760866B2 (en) * | 2017-08-16 | 2023-09-19 | Lg Chem, Ltd. | White pigment comprising ZIF-based powder, polymer resin film and method for changing color of medium using white pigment |
US20200360349A1 (en) * | 2017-11-10 | 2020-11-19 | Novartis Ag | Administration of monobactam for the treatment of urinary tract infection |
CN111511737B (zh) * | 2018-01-29 | 2022-10-18 | 南京明德新药研发有限公司 | 用于治疗细菌感染的单环β-内酰胺化合物 |
JP7179185B2 (ja) * | 2018-12-18 | 2022-11-28 | メッドシャイン ディスカバリー インコーポレイテッド | 医薬の製造おける単環式β-ラクタム化合物の使用 |
KR20220084398A (ko) * | 2019-11-22 | 2022-06-21 | 쑤저우 얼예 파마슈티칼 컴퍼니 리미티드 | 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제 |
EP4079305A4 (en) | 2019-12-19 | 2024-01-10 | Shenzhen Optimum Biological Technology Co., Ltd | APPLICATION OF A COMPOUND IN THE PREPARATION OF DRUG |
CN113754651B (zh) | 2020-06-02 | 2023-04-18 | 中国医学科学院医药生物技术研究所 | 一种β-内酰胺化合物、其用途及其制备方法 |
WO2022027439A1 (en) * | 2020-08-06 | 2022-02-10 | Ningxia Academy Of Agriculture And Forestry Sciences | β-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS |
WO2022185241A1 (en) | 2021-03-04 | 2022-09-09 | Bp Asset Vi, Inc. | Process for manufacturing a monobactam antibiotic |
WO2022185240A1 (en) | 2021-03-04 | 2022-09-09 | Bp Asset Vi, Inc. | Formulation of a monobactam antibiotic |
CN115304594B (zh) * | 2022-10-12 | 2023-02-14 | 苏州二叶制药有限公司 | 磺酰脲环取代的化合物的盐型及其晶型 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ196202A (en) | 1980-02-07 | 1984-07-31 | Squibb & Sons Inc | Beta-lactam antibiotics (of azetidine-sulphonic acid type) |
US4775670A (en) | 1980-09-29 | 1988-10-04 | E. R. Squibb & Sons, Inc. | 2-oxo-1-azetidinesulfonic acid salts |
EP0048953B1 (en) | 1980-09-29 | 1988-03-09 | E.R. Squibb & Sons, Inc. | Beta-lactam antibiotics |
WO1982001873A1 (en) | 1980-12-05 | 1982-06-10 | Takeda Chemical Industries Ltd | 1-sulfo-2-oxoazetidine derivatives and process for their preparation |
US4782147A (en) | 1980-12-05 | 1988-11-01 | Takeda Chemical Industries, Ltd. | 1-sulfo-2-oxoazetidine derivatives and their production |
CA1262128A (en) | 1981-08-27 | 1989-10-03 | Christian N. Hubschwerlen | .beta.-lactams |
IL67451A (en) | 1981-12-25 | 1987-10-20 | Takeda Chemical Industries Ltd | 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them |
AU564150B2 (en) * | 1982-04-30 | 1987-08-06 | Takeda Chemical Industries Ltd. | 1-sulfo-2-azetidinone derivatives |
KR900005112B1 (ko) | 1982-05-31 | 1990-07-19 | 반유세이야꾸 가부시끼가이샤 | 2-옥소-1-아제티딘술폰산 유도체의 제조방법 |
DE3377061D1 (en) | 1982-06-03 | 1988-07-21 | Hoffmann La Roche | Process for the preparation of 1-sulfo-2-oxoazetidine derivatives |
JPS6153282A (ja) | 1984-08-22 | 1986-03-17 | Banyu Pharmaceut Co Ltd | 単環β−ラクタム誘導体 |
JPS6153283A (ja) | 1984-08-24 | 1986-03-17 | Banyu Pharmaceut Co Ltd | 2−オキソ−1−アゼチジンスルホン酸誘導体 |
US4610824A (en) | 1984-10-09 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Hydrazide derivatives of monocyclic beta-lactam antibiotics |
US5112968A (en) | 1989-07-28 | 1992-05-12 | E. R. Squibb & Sons, Inc. | Monobactam hydrazide derivatives |
AU2009310959B2 (en) | 2008-10-31 | 2015-05-07 | Shionogi & Co., Ltd. | Cephalosporin having catechol group |
MX2011006541A (es) * | 2008-12-19 | 2011-07-20 | Pfizer | Monocarbamas. |
AU2011336209B2 (en) | 2010-11-29 | 2015-03-19 | Pfizer Inc. | Monobactams |
UY34585A (es) * | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso |
CN103044416A (zh) | 2012-12-17 | 2013-04-17 | 浙江华方药业有限责任公司 | 一种卡芦莫南钠的合成方法 |
US20160326157A1 (en) | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
BR112016020333B1 (pt) * | 2014-03-24 | 2022-08-09 | Novartis Ag | Compostos orgânicos de monobactam, seus usos, composições e combinações farmacêuticas |
-
2016
- 2016-09-20 RU RU2018114480A patent/RU2754180C2/ru active
- 2016-09-20 EA EA201890771A patent/EA037569B1/ru not_active IP Right Cessation
- 2016-09-20 HU HUE16848099A patent/HUE050849T2/hu unknown
- 2016-09-20 ES ES16848099T patent/ES2817537T3/es active Active
- 2016-09-20 PT PT168480994T patent/PT3353175T/pt unknown
- 2016-09-20 MX MX2018003592A patent/MX2018003592A/es active IP Right Grant
- 2016-09-20 KR KR1020187011354A patent/KR20180054816A/ko not_active Application Discontinuation
- 2016-09-20 EP EP16848099.4A patent/EP3353175B1/en active Active
- 2016-09-20 JP JP2018515607A patent/JP6837480B2/ja active Active
- 2016-09-20 CA CA2999794A patent/CA2999794C/en active Active
- 2016-09-20 CN CN201680055680.4A patent/CN108137573B/zh active Active
- 2016-09-20 LT LTEP16848099.4T patent/LT3353175T/lt unknown
- 2016-09-20 WO PCT/CN2016/099482 patent/WO2017050218A1/en active Application Filing
- 2016-09-20 RS RS20201038A patent/RS60805B1/sr unknown
- 2016-09-20 MA MA42946A patent/MA42946B1/fr unknown
- 2016-09-20 EA EA202092620A patent/EA202092620A1/ru unknown
- 2016-09-20 DK DK16848099.4T patent/DK3353175T3/da active
- 2016-09-20 US US15/762,724 patent/US10919887B2/en active Active
- 2016-09-20 AU AU2016327264A patent/AU2016327264B2/en active Active
- 2016-09-20 SI SI201630906T patent/SI3353175T1/sl unknown
-
2018
- 2018-03-20 IL IL258254A patent/IL258254B/en active IP Right Grant
- 2018-03-21 CL CL2018000745A patent/CL2018000745A1/es unknown
- 2018-03-23 PH PH12018500653A patent/PH12018500653A1/en unknown
- 2018-12-21 HK HK18116415.3A patent/HK1257271A1/zh unknown
-
2019
- 2019-11-20 CL CL2019003324A patent/CL2019003324A1/es unknown
-
2020
- 2020-09-07 HR HRP20201423TT patent/HRP20201423T1/hr unknown
- 2020-09-07 CY CY20201100840T patent/CY1123509T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000745A1 (es) | Sales y formas solidas del acido 1-(((z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoazetidin-3-il)amino)etilideno)amino)oxi)ciclopropanocarboxilico; metodos de preparacion; formas cristalinas; composicion farmaceutica; uso en el tratamiento de una infeccion bacteriana gram negativa. | |
WO2016109663A3 (en) | Derivatives and methods of treating hepatitis b infections | |
WO2016131067A3 (en) | Pharmaceutical compositions comprising meloxicam | |
EP3505620A4 (en) | 2D ORGANOID FOR INFECTIONS AND GROWTH OF HUMAN DIARRHOEVIRUS AND USE OF THE TWO-DIMENSIONAL ORGANOID | |
CL2015003298A1 (es) | Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
DK3805233T3 (da) | (r)- og (s)-enantiomerer af n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazol-carboxamid som irak4-hæmmere til cancerbehandling | |
WO2015170322A3 (en) | Compositions and methods of using same for increasing resistance of infected mosquitoes | |
CL2013000399A1 (es) | Compuestos derivados de ester de acido boronico; composicion farmaceutica; recipiente esteril; metodo de preparacion; y su uso para el tratamiento o la prevencion de una infeccion bacteriana. | |
CL2012003723A1 (es) | Compuestos derivados de acido 2-quinolinil-acetico; composicion farmaceutica; y uso en el tratamiento del vih y sida. | |
CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
CL2014000470A1 (es) | Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana. | |
CL2011002941A1 (es) | Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoico y acido monobenzoico de 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo; composicion farmaceutica; y uso en el tratamiento de asma, epoc, cancer, vih, hepatitis b y c, infecciones bacterianas. | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
CL2014000149A1 (es) | Metodo para sintetizar n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil) fenil)]acetamida y mesilato monohidrato cristalino del mismo; composicion farmaceutica que lo contiene; combinacion farmaceutica; uso en el tratamiento y/o profilaxis de una infeccion por virus herpes simplex. | |
AR103680A1 (es) | Inhibidores selectivos de bace1 | |
WO2009009759A3 (en) | Yersinia pestis antigens, vaccine compositions, and related methods | |
CL2013003229A1 (es) | Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc. | |
AR085856A1 (es) | Formas cristalinas del acido (2s)-2-ter-butoxi-2-(4-(2,3-dihidropirano[4,3,2-de]quinolin-7-il)-2-metilquinolin-3-il)acetico | |
CL2015002755A1 (es) | Composiciones antibióticas de ceftolozano. | |
BR112017004673A2 (pt) | formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida | |
WO2015024010A3 (en) | Substituted hydroxamic acid compounds | |
CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
CR20170314A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
WO2016086153A3 (en) | Use of hsp90 inhibitors for the treatment of hiv infections and aids |